Exchange: NASDAQ·Updated 07:34 PM EDT
News
all
press releases
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -72.00% and -65.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
S&P 500, Nasdaq, Dow End Higher Led By Chipmaker Stocks As Investors Look Past US-Iran Hostility — ORCL, SBUX, WULF, PANW, FATE In Focus
The United States carried out a second consecutive day of new military operations against Iran.
Stocktwits
FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials
The clearance allows the company to begin an early-stage basket trial in multiple autoimmune diseases later this year.
Stocktwits
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire NEW YORK, June 30, 2026 Issued on behalf of GT Biopharma, Inc.GT...
PR Newswire
The $13 Million Company Teaching the Immune System to Hunt Cancer
The $13 Million Company Teaching the Immune System to Hunt Cancer The $13 Million Company Teaching the Immune System to Hunt Cancer PR Newswire NEW YORK, May 29, 2026 Issued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)Three drugs in human trials. A platform licensed from one of the world's top...
PR Newswire
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets PR Newswire NEW YORK, May 20, 2026 Cell therapies and precision biologics are driving new...
PR Newswire
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes PR Newswire SAN FRANCISCO, May 19, 2026 Equity Insider News...
PR Newswire
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth...
PR Newswire
Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +10.87% and -25.77%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates
CAMP4 Therapeutics Corporation (CAMP) delivered earnings and revenue surprises of -49.53% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.